Drug updated on 10/23/2023
|Injection (intravenous: 500 mg/8 mL (62.5 mg/mL))
|Ongoing and Completed Studies
- For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Product Monograph / Prescribing Information
|Sotrovimab (anti-SARS-CoV-2 spike protein monoclonal antibody) Prescribing Information.
|GlaxoSmithKline Inc., Mississauga, Ontario
Systematic Reviews / Meta-Analyses
|Sotrovimab therapy in solid organ transplant recipients with mild to moderate COVID-19: a systematic review and meta-analysis.
|Immunopharmacology and Immunotoxicology
|Efficacy and safety of sotrovimab in patients with COVID-19: a rapid review and meta-analysis.
|Reviews in Medical Virology
|Lack of efficacy for sotrovimab use in patients with COVID-19: a meta-analysis.
|Journal of Infection
Clinical Practice Guidelines
|A living WHO guideline on drugs for COVID-19.